Commercial manufacture of Bluebird’s gene therapy begins, launched in Germany 16-Jan-2020 By Ben Hargreaves Apceth announces that it has started the commercial manufacture of Zyntelgo, after health insurance companies in Germany agree to pricing structure.
Bluebird chooses partner for manufacture of its first approved product 13-Jun-2019 By Ben Hargreaves Apceth announces that it will be responsible for the commercial manufacture of Zyntelgo, after its approval last week.
Bluebird has lift off with first gene therapy approval 04-Jun-2019 By Ben Hargreaves Bluebird has received EU conditional marketing approval for patients with transfusion-dependent β-thalassemia, becoming the first treatment from its pipeline to receive approval.
